Novo Nordisk A/S - share repurchase programme
May 27, 2024 08:49 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Global Hormone Replacement Therapy Research Report 2024: A $35+ Billion Market by 2032 - Industry Trends, Share, Growth, Insight, Top Companies
May 24, 2024 07:48 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Hormone Replacement Therapy Market, Size, Forecast 2024-2032, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies...
Global Diabetes Drug Analysis Report 2024: A $107.02 Billion Market by 2032 Driven by Novo Nordisk, AstraZeneca, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Novartis
May 24, 2024 07:07 ET
|
Research and Markets
Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetes Drug Market Report by Drug class, Diabetes types, Route of Administration, Distribution Channels, Region and Company Analysis 2024-2032"...
Veru to Present at the Jefferies Global Healthcare Conference
May 22, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Novo Nordisk A/S - share repurchase programme
May 17, 2024 10:20 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Type 1 Diabetes Market Size to Worth USD 24.36 Bn By 2031
May 16, 2024 05:30 ET
|
CMI
Burlingame, May 16, 2024 (GLOBE NEWSWIRE) -- The global type 1 diabetes market is estimated to be valued at USD 15.95 Bn in 2024 and is expected to reach USD 24.36 Bn by 2031, according to Coherent...
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
May 15, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 15, 2024 07:23 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Aeterna Zentaris Reports First Quarter 2024 Financial Results
May 14, 2024 18:00 ET
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
May 14, 2024 08:30 ET
|
Veru Inc.
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...